Hilda Elizabeth Macias-Cervantes, Marco Antonio Ocampo-Apolonio, Rodolfo Guardado-Mendoza, Miguel Baron-Manzo, Texar Alfonso Pereyra-Nobara, Luis Ricardo Hinojosa-Gutiérrez, Sergio Edgardo Escalante-Gutiérrez, Mario Alberto Castillo-Velázquez, Rodolfo Aguilar-Guerrero
{"title":"Effect of vitamin K1 supplementation on coronary calcifications in hemodialysis patients: a randomized controlled trial.","authors":"Hilda Elizabeth Macias-Cervantes, Marco Antonio Ocampo-Apolonio, Rodolfo Guardado-Mendoza, Miguel Baron-Manzo, Texar Alfonso Pereyra-Nobara, Luis Ricardo Hinojosa-Gutiérrez, Sergio Edgardo Escalante-Gutiérrez, Mario Alberto Castillo-Velázquez, Rodolfo Aguilar-Guerrero","doi":"10.1007/s40620-024-02154-9","DOIUrl":"https://doi.org/10.1007/s40620-024-02154-9","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is associated with several adverse cardiovascular outcomes, including coronary heart disease, heart failure, and arrhythmias. The severity of arterial calcifications predicts the risk of coronary heart disease and increases the risk of premature cardiovascular death. In experimental models, vitamin K1 supplementation appears to reduce coronary artery calcifications.</p><p><strong>Methods: </strong>In this single-center clinical trial (NCT04247087 on 07/09/2019), we randomized 60 Mexican patients on chronic hemodialysis and a coronary calcification score > 10 Agatston units to receive 10 mg intravenous vitamin K1 or placebo at the end of the hemodialysis session thrice weekly for 12 months. The primary outcome was the progression of coronary artery calcifications as assessed by the absolute change in Agatston and coronary calcium volume scores.</p><p><strong>Results: </strong>The baseline coronary calcium score was 112.50 (14-2027) Agatston units in the vitamin K1 group and 177 (10-2843); Agatston units in the placebo group (p = 0.71), and after 12 months, the coronary calcium score in the vitamin K1 group was 78.50 (10-1915) Agatston units in the vitamin K1 group versus 344 (10-3323); Agatston units (p = 0.05) in the placebo group. Progression of coronary calcification was 20.8% in the vitamin K1 group versus 44% in the placebo group, with a relative risk (RR) of 0.45 (CI 95% 0.18-1.15).</p><p><strong>Conclusions: </strong>In the Mexican hemodialysis cohort enrolled in this study intravenous vitamin K1 supplementation reduced the progression of coronary artery calcifications by 55% compared with placebo over a 12-month follow-up period.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Salvatore De Cosmo, Roberto Pontremoli, Annalisa Giandalia, Valeria Manicardi, Alberto Rocca, Antonio Nicolucci, Maria Chiara Rossi, Giuseppe Lucisano, Giusi Graziano, Paolo Di Bartolo, Graziano Di Cianni, Riccardo Candido, Giuseppina T Russo
{"title":"Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies.","authors":"Salvatore De Cosmo, Roberto Pontremoli, Annalisa Giandalia, Valeria Manicardi, Alberto Rocca, Antonio Nicolucci, Maria Chiara Rossi, Giuseppe Lucisano, Giusi Graziano, Paolo Di Bartolo, Graziano Di Cianni, Riccardo Candido, Giuseppina T Russo","doi":"10.1007/s40620-024-02171-8","DOIUrl":"https://doi.org/10.1007/s40620-024-02171-8","url":null,"abstract":"<p><strong>Background: </strong>We evaluated the proportion of Type 2 diabetes (T2D) patients with chronic kidney disease (CKD) participating in the AMD (Association of Medical Diabetologists) Annals initiative who met the eligibility criteria for phase III-studies on finerenone, showing its renal and cardiovascular benefits.</p><p><strong>Methods: </strong>This analysis involved all T2D patients seen in 2019 in 282 diabetes centers in Italy, for whom data on kidney function (estimated glomerular filtration rate and albuminuria) were available. Data are presented separately for different scenarios, covering the population with main eligibility criteria for inclusion in the FIDELIO-DKD and FIGARO-DKD trials.</p><p><strong>Results: </strong>Among 343,037 T2D patients involved in the analysis, 5.4% met the eligibility criteria of the FIDELIO-DKD study (13.3% if we consider the population with fundus data) and 22.3% met those of the FIGARO-DKD trial. Overall, 110,000 (33%) patients were eligible for treatment with finerenone, with a male prevalence, an average age of 71 years, and good control of the main risk factors (HbA1c 7.3%; BP 138/76 mmHg; LDL-c 87 mg/dl), albeit with large percentages of not well controlled patients (50% with SBP > 140 mmHg; > 30% with LDL-c > 100 mg/dl). Over 12% were on sodium/glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists. Based on the event rate from the FIDELITY pooled analysis, the number of potentially avoidable events was 21.7 per 1000 eligible patients for the cardiovascular composite outcome and 16.7 for the renal outcome.</p><p><strong>Conclusions: </strong>This analysis showed that approximately 33% of patients with T2D present the main eligibility criteria for treatment with finerenone and could therefore benefit from it in the near future.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison between female kidney donors with prediabetes and without diabetes in blood pressure measurements, kidney and diabetes biomarkers: a prospective cohort study.","authors":"Mahdi Tarabeih, Wasef Na'amnih","doi":"10.1007/s40620-024-02168-3","DOIUrl":"https://doi.org/10.1007/s40620-024-02168-3","url":null,"abstract":"<p><strong>Background: </strong>A comprehensive evaluation of potential living kidney donors is crucial to ensure their short and long-term safety. We explored differences in kidney biochemical indicators, blood pressure measurements, and glucose control pre- and post-kidney donation between women with pre-diabetes and those with normal glucose levels.</p><p><strong>Methods: </strong>We performed a prospective cohort study at West Bank and Gaza University hospitals between 2016 and 2022. Differences in sociodemographic and clinical factors that were collected from the participants' medical records between women with pre-diabetes and without diabetes, pre- and post-donation, were assessed using the chi-square test for categorical variables and the Mann-Whitney U test for variables with skewed distribution. Trained nurses performed anthropometric measurements and drew fasting blood samples at various time points from one year before donation to five years after donation.</p><p><strong>Results: </strong>Altogether, 114 female kidney donors (57 with pre-diabetes) aged 27-45 years (median = 35.7, IQR = 5.6) were included in the study. The post-donation median Body Mass Index (BMI) remained higher in women with pre-diabetes (35.02) than in those without diabetes (29.34) five years after donation, (P < 0.001). The 24 h protein, diastolic, and systolic blood pressure levels were significantly higher among women with pre-diabetes than among those without diabetes five years after donation, (P < 0.001). The median estimated glomerular filtration rate (eGFR) was significantly lower in pre-diabetic women (78.2 ml/min/1.73 m<sup>2</sup>) compared with the non-diabetic participants (87.9 ml/min/1.73 m<sup>2</sup>) five years after donation, (P < 0.001).</p><p><strong>Conclusions: </strong>Pre-diabetic donors showed an increased risk of adverse outcomes, including hypertension, impaired oral glucose tolerance test, worsening kidney function, and proteinuria. Our findings underscore the importance of maintaining regular check-ups and follow-ups in particular in pre-diabetic kidney donors.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arthur Michon-Colin, Yannis Lombardi, Guillaume Seret, Frédéric Lavainne, Angelo Testa, Hamza Ayari, Guy Rostoker, Pablo Antonio Urena Torres, Maxime Touzot
{"title":"Impact of iron and erythropoiesis-stimulating agent dose on mortality of hemodialysis patients with cancer.","authors":"Arthur Michon-Colin, Yannis Lombardi, Guillaume Seret, Frédéric Lavainne, Angelo Testa, Hamza Ayari, Guy Rostoker, Pablo Antonio Urena Torres, Maxime Touzot","doi":"10.1007/s40620-024-02162-9","DOIUrl":"https://doi.org/10.1007/s40620-024-02162-9","url":null,"abstract":"","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elisa Longhitano, Federica Bellone, Valeria Cernaro, Giovanni Squadrito, Domenico Santoro
{"title":"Idiopathic inflammatory myopathy and C3 glomerulopathy: a rare association.","authors":"Elisa Longhitano, Federica Bellone, Valeria Cernaro, Giovanni Squadrito, Domenico Santoro","doi":"10.1007/s40620-024-02148-7","DOIUrl":"https://doi.org/10.1007/s40620-024-02148-7","url":null,"abstract":"<p><p>Idiopathic inflammatory myopathies represent a spectrum of autoimmune disorders primarily characterized by muscle inflammation. While renal involvement in idiopathic inflammatory myopathies has historically been considered rare, recent findings indicate a prevalence of approximately 21-23%. Renal manifestations in idiopathic inflammatory myopathies are generally secondary to acute renal injury from rhabdomyolysis or, more rarely, occur through autoimmune mechanisms leading to glomerulonephritis. Here, we present the case of a 21-year-old male diagnosed with idiopathic inflammatory myopathy positive for anti-Jo antibodies and concurrent C3 glomerulonephritis, which improved following Rituximab therapy. The description of this case provides insights for future research into the role of alternative complement pathway dysregulation in idiopathic inflammatory myopathy-associated C3 glomerulopathy.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Will beauty save the world? : Books as medicine: a small contribution to humanities in nephrology.","authors":"Giorgina Barbara Piccoli","doi":"10.1007/s40620-024-02187-0","DOIUrl":"https://doi.org/10.1007/s40620-024-02187-0","url":null,"abstract":"","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rifampicin-induced acute kidney injury due to pigment nephropathy: a lesson for the clinical nephrologist.","authors":"Pankaj Jawandhiya, Gayatri Dhote, Ankur Gupta, Vandana Admane, Jitesh Atram","doi":"10.1007/s40620-024-02129-w","DOIUrl":"https://doi.org/10.1007/s40620-024-02129-w","url":null,"abstract":"","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marcin Kleibert, Kamil Tkacz, Katarzyna Winiarska, Jolanta Małyszko, Agnieszka Cudnoch-Jędrzejewska
{"title":"The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease.","authors":"Marcin Kleibert, Kamil Tkacz, Katarzyna Winiarska, Jolanta Małyszko, Agnieszka Cudnoch-Jędrzejewska","doi":"10.1007/s40620-024-02152-x","DOIUrl":"https://doi.org/10.1007/s40620-024-02152-x","url":null,"abstract":"<p><p>According to the 10th edition of the IDF Diabetes Atlas, 537 million people suffered from diabetes in 2021, and this number will increase by 47% by 2045. It is estimated that even 30-40% of these individuals may develop diabetic kidney disease (DKD) in the course of diabetes. DKD is one of the most important complications of diabetes, both in terms of impact and magnitude. It leads to high morbidity and mortality, which subsequently impacts on quality of life, and it carries a high financial burden. Diabetic kidney disease is considered a complex and heterogeneous entity involving disturbances in vascular, glomerular, podocyte, and tubular function. It would appear that hypoxia-inducible factors (HIF)-1 and HIF-2 may be important players in the pathogenesis of this disease. However, their exact role is still not fully investigated. In this article, we summarize the current knowledge about HIF signaling and its role in DKD. In addition, we focus on the possible effects of nephroprotective drugs on HIF expression and activity in various tissues.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Longitudinal studies: focus on trajectory analysis in kidney diseases.","authors":"Carmine Zoccali, Giovanni Tripepi","doi":"10.1007/s40620-024-02167-4","DOIUrl":"https://doi.org/10.1007/s40620-024-02167-4","url":null,"abstract":"<p><p>Longitudinal cohort studies are pivotal in medical research for understanding disease progression over time. These studies track a group of individuals across multiple time points, enabling the identification of risk factors and the evaluation of interventions. Traditional methods like linear mixed models, generalized estimating equations, and survival analysis often fall short in capturing the complex, non-linear patterns of disease progression. Trajectory analysis, a statistical technique that identifies distinct paths within longitudinal data, offers a more nuanced approach. This review delves into the methodological foundations of trajectory analysis, including data preparation, model selection, parameter estimation, model evaluation, and interpretation. It highlights the advantages of trajectory analysis, such as its ability to capture heterogeneity, handle various data types, and enhance predictive power. The application of trajectory analysis in nephrology, particularly in chronic kidney disease and diabetic nephropathy, demonstrates its utility in identifying distinct subgroups with different disease trajectories. Studies have shown that trajectory analysis can uncover patterns of renal function decline and proteinuria progression, providing insights that inform personalized treatment strategies. Despite its strengths, trajectory analysis requires advanced statistical knowledge, computational resources, and large sample sizes, which can be barriers for some researchers. Nevertheless, its ability to reveal complex disease patterns and improve predictive accuracy makes it a valuable tool in longitudinal studies. This review underscores the potential of trajectory analysis to enhance our understanding of disease progression and improve patient outcomes in nephrology and beyond.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sonja Brennan, Donna Rudd, David Watson, Yogavijayan Kandasamy
{"title":"The relationship between maternal health during pregnancy and infant kidney development: a prospective cohort study.","authors":"Sonja Brennan, Donna Rudd, David Watson, Yogavijayan Kandasamy","doi":"10.1007/s40620-024-02141-0","DOIUrl":"https://doi.org/10.1007/s40620-024-02141-0","url":null,"abstract":"<p><strong>Background: </strong>The significance of intergenerational impacts on fetal and infant kidney development and function remains to be fully understood. This is particularly relevant for certain populations, for example the Indigenous Australians since their risk of developing chronic kidney disease (CKD) is twice that of non-Indigenous Australians. The aim of this study was to assess the impact of maternal health and kidney size and function on infant kidney development.</p><p><strong>Methods: </strong>This study was open to all pregnant women receiving antenatal care at Townsville University Hospital, Australia. It presents data from a larger, ongoing prospective, longitudinal cohort study which commenced August 2019, involving mother-infant dyads. This manuscript reports on term mother-infants' dyads from singleton pregnancies. Ultrasound was used to measure renal parenchymal thickness, a surrogate for nephron number, of the mother and their newborn. Kidney function was assessed using serum cystatin C and creatinine.</p><p><strong>Results: </strong>Analysis was conducted on 80 mother-infant dyads, 17 Indigenous and 63 non-Indigenous. Multivariate regression modeling showed maternal renal parenchymal thickness (ß = 0.31, p = 0.004), smoking (ß = - 0.70, p = 0.022) and maternal serum cystatin C (ß = - 0.34, p = 0.014) significantly predicted newborn renal parenchymal thickness. No significant differences were found between the maternal and newborn renal parenchymal thickness and function between Indigenous and non-Indigenous participants.</p><p><strong>Conclusions: </strong>Our study suggests that maternal kidney size and function has a significant intergenerational effect on kidney development of their infants. Newborn renal parenchymal thickness was positively associated with maternal renal parenchymal thickness and negatively associated with smoking and maternal serum cystatin C.</p>","PeriodicalId":16542,"journal":{"name":"Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}